Diffuse Large B-cell Lymphoma Germinal Center B-cell Type

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma [Phase 2]

  Phase 2 clinical trial evaluating the effectiveness of ViPOR in relapsed/refractory aggressive B-cell lymphomas; the study includes Diffuse …

• CLINICAL_TRIALS trial_result · 2026-02-27
  Clinical Trial Update: Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma [Phase 1]

  Phase 1 clinical trial update for tegavivint in relapsed or refractory diffuse large B-cell lymphoma, with ongoing recruitment.

• CLINICAL_TRIALS trial_result · 2025-01-29
  Clinical Trial Update: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma [Phase 1]

  A Phase 1 trial evaluating the combination of chemotherapy with TAK-659 as front-line treatment for high-risk diffuse large B-cell lymphoma,…

• CLINICAL_TRIALS trial_result · 2024-10-16
  Clinical Trial Update: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas [Phase 2]

  Phase 2 trial evaluating nivolumab with or without varlilumab in relapsed or refractory aggressive B-cell lymphomas, including multiple DLBC…